Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryHealth Care Services
SectorMedical
Phone314-996-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$100.06 billion
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Express Scripts (NASDAQ:ESRX) Frequently Asked Questions
What is Express Scripts' stock symbol?
Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."
How will Express Scripts' stock buyback program work?
Express Scripts announced that its board has initiated a stock buyback program on Wednesday, December 20th 2017, which permits the company to buyback 45,000,000 outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company's management believes its stock is undervalued.
How were Express Scripts' earnings last quarter?
Express Scripts Holding Co (NASDAQ:ESRX) released its quarterly earnings results on Wednesday, October, 31st. The company reported $2.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.42 by $0.01. The business earned $25.56 billion during the quarter, compared to analyst estimates of $25.11 billion. Express Scripts had a net margin of 4.83% and a return on equity of 25.43%. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the business earned $2.51 earnings per share. View Express Scripts' Earnings History.
What price target have analysts set for ESRX?
9 equities research analysts have issued 12 month price objectives for Express Scripts' stock. Their predictions range from $81.00 to $101.00. On average, they anticipate Express Scripts' stock price to reach $93.9286 in the next twelve months. This suggests a possible upside of 1.7% from the stock's current price. View Analyst Price Targets for Express Scripts.
What is the consensus analysts' recommendation for Express Scripts?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Express Scripts in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Express Scripts.
Has Express Scripts been receiving favorable news coverage?
News coverage about ESRX stock has been trending somewhat positive this week, according to InfoTrie. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Express Scripts earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the next few days.
Who are some of Express Scripts' key competitors?
What other stocks do shareholders of Express Scripts own?
Who are Express Scripts' key executives?
Express Scripts' management team includes the folowing people:
- Mr. Timothy C. Wentworth, CEO, Pres & Director (Age 58)
- Mr. James M. Havel, Exec. VP & CFO (Age 63)
- Mr. David A. Queller, Sr. VP of Sales & Account Management (Age 49)
- Ms. Christine Houston, Exec. VP of Strategic Integrations (Age 55)
- Mr. Everett Neville, Exec. VP of Strategy, Supply Chain & Specialty (Age 53)
Who are Express Scripts' major shareholders?
Express Scripts' stock is owned by a number of of institutional and retail investors. Top institutional investors include B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund (0.00%), Actinver Wealth Management Inc. (0.00%), Actinver Wealth Management Inc. (0.00%), Meiji Yasuda Asset Management Co Ltd. (0.00%) and Wealthquest Corp (0.00%). Company insiders that own Express Scripts stock include Christine Houston, Everett Neville, Glen D Stettin, Mahon Thomas P Mac, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.
Which institutional investors are selling Express Scripts stock?
ESRX stock was sold by a variety of institutional investors in the last quarter, including Meiji Yasuda Asset Management Co Ltd.. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston and Mahon Thomas P Mac. View Insider Buying and Selling for Express Scripts.
Which institutional investors are buying Express Scripts stock?
ESRX stock was acquired by a variety of institutional investors in the last quarter, including B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund, Actinver Wealth Management Inc., Actinver Wealth Management Inc. and Wealthquest Corp. View Insider Buying and Selling for Express Scripts.
How do I buy shares of Express Scripts?
Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Express Scripts' stock price today?
One share of ESRX stock can currently be purchased for approximately $92.33.
How big of a company is Express Scripts?
Express Scripts has a market capitalization of $52.06 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.10 on an earnings per share basis.
What is Express Scripts' official website?
How can I contact Express Scripts?
Express Scripts' mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]
MarketBeat Community Rating for Express Scripts (NASDAQ ESRX)
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe ESRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
